CCND1 and pancreatic neoplasm: These results indicate that the ivermectin–gemcitabine combination inhibits the formation of cyclin D1 and CDK4/6 complexes in pancreatic cancer, inhibits G1-S cell cycle transition, and induces G1 phase arrest.